Prime Vector Technologies


Prime Vector Technologies (PRIME) is a clinical stage biotech company from Tübingen, Germany, developing vaccines based on a proprietary Orf virus vector platform technology. We offer licenses for platform technology, as well as customer-specific and fully-owned vaccine products for the prevention and therapy of infectious diseases and cancer, respectively. Our single vectored vaccines elicit strong cellular and protective humoral immune responses, are safe and well tolerated by humans, and can be designed to express multiple antigens and immunostimulatory molecules simultaneously to orchestrate the immune system to maximize immunity. Importantly, due to a lack of neutralizing anti-vector immunity, our vaccines can be administrated repeatedly without loss of efficacy and need for an adjuvant. PRIME was spun-off the University Hospital in Tübingen in 2019 in the frame of an EXIST research transfer funding granted from the German Federal Ministry for Economic Affairs and Climate Action. In the past 3 years, we secured first industrial partnerships (incl. Boehringer Ingelheim), established a robust GMP compliant CMC process and advanced a 2nd generation multivalent SARS-CoV-2 vaccine into the clinics to eventually achieve proof-of-concept in humans.